



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to  
Lancet Respir Med 2022;  
published online July 27.  
[https://doi.org/  
10.1016/S2213-  
2600\(22\)00185-0](https://doi.org/10.1016/S2213-2600(22)00185-0)**

Kole TM, Vanden Berghe, Kraft M, et al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. *Lancet Respir Med* 2022; published online July 27. [https://doi.org/10.1016/S2213-2600\(22\)00185-0](https://doi.org/10.1016/S2213-2600(22)00185-0)—In this Article, Klaus F Rabe's affiliation should have been "LungenClinic Grosshansdorf, Airway Research Center North in the German Center for Lung Research, Grosshansdorf, Germany". This correction has been made to the online version as of Oct 21, 2022, and will be made to the printed version.

**Correction to  
Lancet Respir Med 2022;  
10: 972–84**

*ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.* *Lancet Respir Med* 2022; **10**: 972–84—In this Article, Thomas L Holland and Ivan Kimuli should have been included in the ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. This correction has been made to the online version as of Nov 7, 2022.

**Correction to  
Lancet Respir Med 2022;  
10: 700–14**

CaseyJD, Beskow LM, Brown J, et al. *Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.* *Lancet Respir Med* 2022; **10**: 700–14—In this Personal View, a statement from Alexandre Mebazaa was missing from the authors' declaration of interests; the full declaration is now included. This correction has been made to the online version as of Nov 2, 2022.



Published Online  
October 21, 2022  
[https://doi.org/10.1016/  
S2213-2600\(22\)00415-5](https://doi.org/10.1016/S2213-2600(22)00415-5)

Published Online  
November 7, 2022  
[https://doi.org/10.1016/  
S2213-2600\(22\)00441-6](https://doi.org/10.1016/S2213-2600(22)00441-6)

Published Online  
November 2, 2022  
[https://doi.org/10.1016/  
S2213-2600\(22\)00436-2](https://doi.org/10.1016/S2213-2600(22)00436-2)